Why the study?
There is a lack of evidence regarding the optimal revascularization strategy in patients with non-ST-elevation acute coronary syndrome and multivessel disease.
Does percutaneous coronary intervention reduce all-cause mortality at 1 year compared to coronary artery bypass graft surgery in patients with non-ST-elevation acute coronary syndrome and multivessel disease?
Comparison
PCI vs CABG
Design
Systematic review and meta-analysis
Follow-up
1 year
Key result
Percutaneous coronary intervention and coronary artery bypass grafting resulted in similar 1-year all-cause mortality in patients with NSTE-ACS and multivessel disease (OR 0.91; 95% CI 0.68-1.21; P=0.51).
Authors
Loading...
PCI and CABG yield similar 1-year mortality; confirms comparable safety and supports individualized choice in NSTE-ACS multivessel disease.
Systematic Review and Meta-Analysis (n=3,172)
Does percutaneous coronary intervention reduce all-cause mortality at 1 year compared to coronary artery bypass graft surgery in patients with non-ST-elevation acute coronary syndrome and multivessel disease?
Effect estimate: OR 0.91 (95% CI 0.68 to 1.21)
p-value: p=0.51
In patients with NSTE-ACS and multivessel disease, PCI and CABG have similar 1-year rates of mortality, MI, and stroke, though PCI is associated with a higher rate of repeat revascularization.
Kakar et al. (2023) conducted a systematic review and meta-analysis in Non-ST-elevation acute coronary syndrome (NSTE-ACS) and multivessel disease (MVD) (n=3,172). Percutaneous coronary intervention (PCI) vs. Coronary artery bypass graft surgery (CABG) was evaluated on All-cause mortality at 1 year (OR 0.91, 95% CI 0.68 to 1.21, p=0.51). Percutaneous coronary intervention and coronary artery bypass grafting resulted in similar 1-year all-cause mortality in patients with NSTE-ACS and multivessel disease (OR 0.91; 95% CI 0.68-1.21; P=0.51).